(Q44603323)

4 December 2017

Linezolid versus vancomycin in the treatment of known or suspected resistant gram-positive infections in neonates (English)

1 reference

4 December 2017

Linezolid versus vancomycin in the treatment of known or suspected resistant Gram-positive infections in neonates (English)

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000086955.93702.C7

16 March 2024

main subject

gram-positive bacteria

0 references

1 reference

1 reference

Stuart Adler

2

1 reference

4 December 2017

Maria Rayo Morfin

5

1 reference

4 December 2017

Sandra Beltran

6

1 reference

4 December 2017

Barbara Edge-Padbury

7

1 reference

4 December 2017

Sharon Naberhuis-Stehouwer

8

1 reference

4 December 2017

Jaime G. Deville

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14520141

16 March 2024

Parvin H. Azimi

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14520141

16 March 2024

Barbara A. Jantausch

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14520141

16 March 2024

Jon B. Bruss

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14520141

16 March 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14520141

16 March 2024

publication date

1 September 2003

1 reference

Pediatric Infectious Disease Journal

4 December 2017

1 reference

4 December 2017

22

1 reference

4 December 2017

9 Suppl

1 reference

4 December 2017

S158-63

1 reference

Prevalence of nosocomial infections in neonatal intensive care unit patients: Results from the first national point-prevalence survey

4 December 2017

1

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000086955.93702.C7

Occurrence of nosocomial bloodstream infections in six neonatal intensive care units

16 March 2024

2

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000086955.93702.C7

Nosocomial infections in pediatric intensive care units in the United States. National Nosocomial Infections Surveillance System.

16 March 2024

3

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000086955.93702.C7

Evaluation and treatment of neonates with suspected late-onset sepsis: a survey of neonatologists' practices

16 March 2024

4

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000086955.93702.C7

The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria

16 March 2024

5

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000086955.93702.C7

In vitro activities in new oxazolidinone antimicrobial agents against enterococci

16 March 2024

7

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000086955.93702.C7

In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents

16 March 2024

8

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000086955.93702.C7

In vitro activities of the oxazolidinone antibiotics U-100592 and U-100766 against Staphylococcus aureus and coagulase-negative Staphylococcus species

16 March 2024

9

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000086955.93702.C7

Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections

16 March 2024

12

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000086955.93702.C7

Single dose pharmacokinetics of linezolid in infants and children.

16 March 2024

13

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000086955.93702.C7

Linezolid for the treatment of community-acquired pneumonia in hospitalized children. Linezolid Pediatric Pneumonia Study Group

16 March 2024

14

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000086955.93702.C7

Linezolid versus cefadroxil in the treatment of skin and skin structure infections in children

16 March 2024

15

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000086955.93702.C7

Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children

16 March 2024

16

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000086955.93702.C7

Late-onset sepsis in very low birth weight neonates: a report from the National Institute of Child Health and Human Development Neonatal Research Network

16 March 2024

17

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000086955.93702.C7

Bacteremia, central catheters, and neonates: when to pull the line

16 March 2024

19

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000086955.93702.C7

Central venous catheter removal versus in situ treatment in neonates with coagulase-negative staphylococcal bacteremia

16 March 2024

20

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000086955.93702.C7

Epidemiology of vancomycin usage at a children's hospital, 1993 through 1995.

16 March 2024

21

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000086955.93702.C7

The emergence of decreased susceptibility to vancomycin in Staphylococcus epidermidis.

16 March 2024

22

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000086955.93702.C7

Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group

16 March 2024

23

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000086955.93702.C7

16 March 2024

Identifiers

1 reference

4 December 2017

1 reference